|
 
- 积分
- 429
- 威望
- 429
- 包包
- 1768
|
本帖最后由 qianqianlaile 于 2011-3-21 11:29 编辑 ( O+ w7 c& I# L) }" m2 p. j
4 ]. y" M. `3 c+ U" tINTRODUCTION
2 @6 b6 m3 ?* y: j$ j4 \Cell therapy has tremendous potential in regenerative medicine, yet, there are concerns in 2 n/ s, T/ U' e/ V& s/ U/ m: `
the utility of cell therapy due to questions regarding different cell harvest and cultivation & G4 d* `! B- n0 y! R5 _1 n0 S2 w
methods (Haack-Sorensen et al., 2008; Mannello and Tonti, 2007). Bone marrow derived
. k! V/ P% p3 Ystem cells have been identified for a number of years, and there are a number of
$ K9 I. D5 t3 Uongoing clinical trials exploring the safety and efficacy of their use for a number of ( K1 U9 ]+ R8 l" K* A
clinical applications (Battiwalla and Hematti, 2009; Sadan et al., 2009; Satija et al.,
- _0 n: o: Z: X! j# F2 `/ M$ C" O2009). There has been an increased interest in recent years in the potential of oral-* v0 A! k" {/ x9 S# I4 g+ h
derived stem cells for cell therapy, primarily because they can be derived from a readily
* }; B( Z* n# a: navailable source, extracted teeth (Gronthos et al., 2000; Miura et al., 2003; Seo et al., 0 A1 @$ F( c) k6 s7 N% w) H* W4 z
2004). These cells exhibit multipotency and regenerative capacities characteristic of % j, {, G# l8 V- A/ U
mesenchymal stem cells (Batouli et al., 2003; Shi et al., 2005) and have the capacity to - c# x y: h3 h/ Y5 y: e
repair and regenerate tooth structures in vivo (Krebsbach and Robey, 2002; Mao et al., 2006). % n: _- v) u+ R/ M+ h5 ?4 s
Because oral-derived stem cells have been more recently identified, clinical
" I7 [( S$ O6 f% L2 g9 Xprotocols are still being developed for their use. Regardless of the specific protocol
6 E/ X: ] v- d: X( uused, most current cell therapy approaches rely upon ex vivo cell expansion in order to
0 o( t* F. r- W4 K+ G% Vproduce sufficient cell numbers for transplantation. Though a wide variety of protocols " E, _4 p1 N; H- V7 [% l/ J
and culturing methods exist, one common aspect to most of them is the inclusion of 4 ]" T5 J( H1 g1 I! [& b* q" a b
animal sera for cell expansion, in that it contains a rich source of nutrients and growth 1 }) o( J) Y9 t& p, m
factors (Mannello and Tonti, 2007). Despite the widespread standard use of animal * D0 ` d0 Q' ^, {' B: ]
sera for in vitro cell culture (Freshney, 2000), there are several problems which exist
, Q1 f8 R4 Q) w. }" arelative to its use for clinical application. " @/ m/ z- g# V
One of the central issues regarding limitations in using animal sera for clinical cell ! U$ h- a+ n# u+ i
therapy protocols is that its components are highly variable and, in many cases,
9 q$ t! e0 A8 A. X5 M9 munknown. Though components of sera have identified, it has also been demonstrated 7 G# y/ M' ]5 `( x5 i& B# ?; O7 z0 {5 s
that consistency between different lots cannot be assured (Price and Gregory, 1982). In ( T2 @! i8 B( z3 t: e0 V3 x! x
the context of multipotent stem cells, serum components and concentrations have 3 C2 R- g$ p! v2 H, M
significant impact on cell survival and proliferative capacity, phenotype, and multipotent
" h+ b& L* e P$ R! v/ @6 rpotential (Agata et al., 2009; Sotiropoulou et al., 2006). Additionally, for clinical use, the
% J$ w: A* J# y! R7 Tinclusion of xenogeneic serum for cell expansion carries immunological risks associated ! X. b4 k& q& u; _ V2 S ^$ s. o
with the immunogenicity of serum proteins and the potential of transmission of prion . E; _3 U5 k" m- X
diseases and zoonoses (Shahdadfar et al., 2005). These concerns have led to efforts
( B( E$ N7 A! v1 Raimed at incorporating FBS alternatives in cell expansion protocols, including the use of ( P$ n8 }7 y6 N: t7 v) P. a
autologous and allogeneic sera, and the proprietary manufacturing of serum-free media
7 \) B- C- i% x F1 tformulations by different companies (Nakamura et al., 2008). Even with these approaches,
- `9 _# j# r. U there are limitations in the availability of both autologous and allogeneic [3 U) _- R/ J; c @$ S- s
sera and companies do not freely disclose their proprietary “serum-free” media ( i2 U8 N8 u7 i8 X" n7 [
components. These factors not only prohibit clinical translation, but also limit
7 B# ?2 l. S8 w; T9 N& Z' Hwidespread use and study of more basic fundamental questions regarding specific
* H; B) h- I8 _8 K9 Amechanisms involved in the modulation of these media on cell function. As such, there
! @3 M% T1 D9 n- J$ ~5 _0 E9 pexists a need for the development of chemically-defined media which can propagate the7 Y, O5 |: d: m( x: I* W- l2 H" [
cultivation of stem cells without adversely affecting cell function and phenotype
$ A V3 {# w/ L9 E. T(Mannello and Tonti, 2007).1 [* {# q$ w' |/ }1 ?' u
In this study, we aimed to develop a serum-free media (K-M) for the expansion o* d5 r+ n" n: H! k+ i) s1 j1 X
dental-derived stem cells, including stem cells-derived from exfoliated deciduous (baby)/ B8 ]3 y* l. F c$ o
teeth (SHEDs) and periodontal ligament stems cells (PDLSCs). Cell expansion in this * z! `. Q6 ^& @
media was compared to standard FBS containing media used to culture these cells, 6 ]* U5 u: L+ ?6 ~5 V- a4 \
as well as three other serum-free media formulations (two of which are commercially available)
" N8 Z' |7 b" H3 e- s( n. tused for culture of mesenchymal stem cells. Additionally, through
3 D$ Z+ \' e, S. O0 _/ _+ idifferentiation assays and microarray analyses, multipotency and differential gene
/ c9 w, b& R3 `% Wexpression of 84 stem cell associated genes was examined between cells cultured in K-
, T C" A5 V: [+ f g( jM vs. those cultured in FBS- containing media. |
|
发表于 2011-3-20 08:21
，脑子里也没有独家生产这个概念
，所以没理解。